Is It Still Worth Considering Liquidia After Its 1,051% Increase Over Five Years?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 16 2025
0mins
Should l Buy LQDA?
Source: Yahoo Finance
Stock Performance: Liquidia's share price has surged 21.9% in the last month and 182.6% year-to-date, driven by optimism around its pulmonary hypertension franchise and regulatory advancements.
Valuation Insights: The company scores only 2 out of 6 on valuation checks, indicating both undervaluation and caution, with a Discounted Cash Flow analysis suggesting it is 82.6% undervalued.
Price to Sales Ratio: Liquidia trades at a high price to sales ratio of 43.0x, significantly above the industry average of 4.2x, indicating that the market may be pricing in overly optimistic growth expectations.
Narrative Framework: Simply Wall St introduces a Narrative framework to help investors assess a company's future potential by translating their views into financial forecasts, allowing for a clearer understanding of fair value compared to market prices.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LQDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LQDA
Wall Street analysts forecast LQDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LQDA is 47.50 USD with a low forecast of 31.00 USD and a high forecast of 67.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 41.560
Low
31.00
Averages
47.50
High
67.00
Current: 41.560
Low
31.00
Averages
47.50
High
67.00
About LQDA
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Liquidia Corp and MP Materials See Surge in Options Trading Volume
- Liquidia Options Activity: Liquidia Corp (LQDA) saw options trading volume of 10,829 contracts, equating to approximately 1.1 million shares, or about 55.9% of its average daily trading volume of 1.9 million shares over the past month, indicating heightened market interest.
- High Volume Insights: Notably, the $40 strike call option expiring January 23, 2026, recorded 1,601 contracts traded today, representing around 160,100 underlying shares of LQDA, suggesting bullish sentiment among investors regarding its price trajectory.
- MP Materials Options Surge: MP Materials Corp (MP) experienced options trading volume of 43,698 contracts, translating to about 4.4 million shares, or approximately 55.5% of its average daily trading volume of 7.9 million shares in the past month, reflecting strong investor engagement.
- Put Option Trading: The $65 strike put option expiring January 23, 2026, saw 2,986 contracts traded today, representing approximately 298,600 underlying shares of MP, indicating market concerns over potential downside risks in its stock price.
See More
Healthcare Sector Outperforms S&P 500 with 12.52% Gain and 3.20 Health Score
- Sector Performance: The S&P 500 healthcare sector achieved a 12.52% gain in 2025, lagging behind the broader S&P 500 index's 16.39% increase, indicating relative strength within the healthcare industry.
- Health Score Analysis: Seeking Alpha's Quant Ratings assign an average health score of 3.20 out of 5 to the healthcare sector, based on 261 stocks with market capitalizations above $2 billion, reflecting a generally healthy outlook for the sector.
- Stock Rating Distribution: Among the 261 stocks, 37 are rated Buy or higher, 213 are Neutral, and 11 are Strong Sell, showcasing varied market perceptions and investment opportunities within the healthcare sector.
- Top Stock Ratings: Ahead of the upcoming earnings season, stocks like Grail (GRAL) and Indivior PLC (INDV) received strong buy ratings of 4.97 and 4.95, respectively, indicating strong investor confidence in these companies.
See More
Liquidia Reports $148.3M in Yutrepia Sales, Shares Surge Nearly 13%
- Strong Sales Performance: Liquidia reported preliminary sales of approximately $148.3 million for Yutrepia in 2025, with $90.1 million generated in the fourth quarter alone, indicating robust market demand for the drug in treating pulmonary arterial hypertension, which is expected to drive further revenue growth for the company.
- Improved Cash Flow: The company generated over $30 million in positive cash flow during the fourth quarter, boosting its cash and cash equivalents to around $190.7 million by the end of 2025, enhancing financial stability and providing support for future investments.
- Future Development Plans: Liquidia aims to strengthen clinical programs for both Yutrepia and its leading investigational drug L606, focusing on differentiating these pulmonary arterial hypertension treatments to expand market share and enhance competitiveness.
- Significant Market Potential: The rapid market progress of Yutrepia suggests it could become a go-to medication for pulmonary arterial hypertension and related conditions, further solidifying Liquidia's position in the biopharmaceutical sector.
See More
Liquidia Reports $148.3M in Yutrepia Sales, Shares Surge 13%
- Strong Sales Performance: Liquidia reported preliminary sales of approximately $148.3 million for its latest product Yutrepia in 2025, with $90.1 million generated in the fourth quarter alone, indicating robust market demand for the drug in treating pulmonary arterial hypertension, which is expected to further drive revenue growth.
- Improved Cash Flow: The company generated over $30 million in positive cash flow during the fourth quarter, boosting its cash and cash equivalents to around $190.7 million by the end of 2025, providing financial support for future R&D and market expansion.
- Optimistic Market Outlook: Since its FDA approval, Yutrepia has received positive market feedback, with early indications suggesting it could become a go-to medication for pulmonary arterial hypertension and related conditions, thereby strengthening Liquidia's competitive position in the biopharmaceutical sector.
- Clear Future Plans: Liquidia aims to enhance clinical programs for both Yutrepia and its leading investigational drug L606 to further differentiate their offerings and expand potential indications, demonstrating the company's strategic focus on future growth opportunities.
See More
Health Care Stocks Decline as NYSE Health Care Index Falls 0.1%
- Market Performance Weakens: Late Friday afternoon, health care stocks broadly declined, with the NYSE Health Care Index dropping 0.1%, reflecting investor caution regarding the sector's outlook, which may negatively impact short-term stock performance for related companies.
- Investor Sentiment Dims: The decline in health care stocks, driven by increased uncertainty about economic recovery, could lead to capital outflows, thereby affecting companies' financing capabilities and future investment plans.
- Significant Industry Impact: The overall downturn in the health care sector may adversely affect earnings expectations for related firms, especially in the current economic climate where companies face greater operational pressures.
- Increased Market Volatility: As health care stocks decline, investors may reassess their portfolios, leading to heightened market volatility that could impact overall market stability.
See More
CG Oncology Accelerates Phase 3 Data Readout to First Half of 2026
- Significant Stock Surge: Shares of CG Oncology Inc soared 21.8% to $51.05 after the announcement of an expedited topline data readout for the PIVOT-006 clinical trial, reflecting strong market confidence in the company's future prospects.
- Clinical Trial Advancement: The trial compares adjuvant intravesical treatment versus surveillance in patients with intermediate-risk non-muscle invasive bladder cancer, and the earlier data release is expected to attract more investor interest, further propelling the company's growth.
- Positive Market Reaction: This stock price increase not only indicates investor optimism about CG Oncology's potential but may also enhance the company's financing capabilities in the biopharmaceutical sector, strengthening its competitive position.
- Significant Industry Impact: CG Oncology's progress could influence treatment standards for non-muscle invasive bladder cancer, prompting other companies in the industry to accelerate their R&D efforts, thereby boosting overall market vitality.
See More
Liquidia Corp and MP Materials See Surge in Options Trading Volume
- Liquidia Options Activity: Liquidia Corp (LQDA) saw options trading volume of 10,829 contracts, equating to approximately 1.1 million shares, or about 55.9% of its average daily trading volume of 1.9 million shares over the past month, indicating heightened market interest.
- High Volume Insights: Notably, the $40 strike call option expiring January 23, 2026, recorded 1,601 contracts traded today, representing around 160,100 underlying shares of LQDA, suggesting bullish sentiment among investors regarding its price trajectory.
- MP Materials Options Surge: MP Materials Corp (MP) experienced options trading volume of 43,698 contracts, translating to about 4.4 million shares, or approximately 55.5% of its average daily trading volume of 7.9 million shares in the past month, reflecting strong investor engagement.
- Put Option Trading: The $65 strike put option expiring January 23, 2026, saw 2,986 contracts traded today, representing approximately 298,600 underlying shares of MP, indicating market concerns over potential downside risks in its stock price.
See More
Healthcare Sector Outperforms S&P 500 with 12.52% Gain and 3.20 Health Score
- Sector Performance: The S&P 500 healthcare sector achieved a 12.52% gain in 2025, lagging behind the broader S&P 500 index's 16.39% increase, indicating relative strength within the healthcare industry.
- Health Score Analysis: Seeking Alpha's Quant Ratings assign an average health score of 3.20 out of 5 to the healthcare sector, based on 261 stocks with market capitalizations above $2 billion, reflecting a generally healthy outlook for the sector.
- Stock Rating Distribution: Among the 261 stocks, 37 are rated Buy or higher, 213 are Neutral, and 11 are Strong Sell, showcasing varied market perceptions and investment opportunities within the healthcare sector.
- Top Stock Ratings: Ahead of the upcoming earnings season, stocks like Grail (GRAL) and Indivior PLC (INDV) received strong buy ratings of 4.97 and 4.95, respectively, indicating strong investor confidence in these companies.
See More
Liquidia Reports $148.3M in Yutrepia Sales, Shares Surge Nearly 13%
- Strong Sales Performance: Liquidia reported preliminary sales of approximately $148.3 million for Yutrepia in 2025, with $90.1 million generated in the fourth quarter alone, indicating robust market demand for the drug in treating pulmonary arterial hypertension, which is expected to drive further revenue growth for the company.
- Improved Cash Flow: The company generated over $30 million in positive cash flow during the fourth quarter, boosting its cash and cash equivalents to around $190.7 million by the end of 2025, enhancing financial stability and providing support for future investments.
- Future Development Plans: Liquidia aims to strengthen clinical programs for both Yutrepia and its leading investigational drug L606, focusing on differentiating these pulmonary arterial hypertension treatments to expand market share and enhance competitiveness.
- Significant Market Potential: The rapid market progress of Yutrepia suggests it could become a go-to medication for pulmonary arterial hypertension and related conditions, further solidifying Liquidia's position in the biopharmaceutical sector.
See More
Liquidia Reports $148.3M in Yutrepia Sales, Shares Surge 13%
- Strong Sales Performance: Liquidia reported preliminary sales of approximately $148.3 million for its latest product Yutrepia in 2025, with $90.1 million generated in the fourth quarter alone, indicating robust market demand for the drug in treating pulmonary arterial hypertension, which is expected to further drive revenue growth.
- Improved Cash Flow: The company generated over $30 million in positive cash flow during the fourth quarter, boosting its cash and cash equivalents to around $190.7 million by the end of 2025, providing financial support for future R&D and market expansion.
- Optimistic Market Outlook: Since its FDA approval, Yutrepia has received positive market feedback, with early indications suggesting it could become a go-to medication for pulmonary arterial hypertension and related conditions, thereby strengthening Liquidia's competitive position in the biopharmaceutical sector.
- Clear Future Plans: Liquidia aims to enhance clinical programs for both Yutrepia and its leading investigational drug L606 to further differentiate their offerings and expand potential indications, demonstrating the company's strategic focus on future growth opportunities.
See More
Health Care Stocks Decline as NYSE Health Care Index Falls 0.1%
- Market Performance Weakens: Late Friday afternoon, health care stocks broadly declined, with the NYSE Health Care Index dropping 0.1%, reflecting investor caution regarding the sector's outlook, which may negatively impact short-term stock performance for related companies.
- Investor Sentiment Dims: The decline in health care stocks, driven by increased uncertainty about economic recovery, could lead to capital outflows, thereby affecting companies' financing capabilities and future investment plans.
- Significant Industry Impact: The overall downturn in the health care sector may adversely affect earnings expectations for related firms, especially in the current economic climate where companies face greater operational pressures.
- Increased Market Volatility: As health care stocks decline, investors may reassess their portfolios, leading to heightened market volatility that could impact overall market stability.
See More
CG Oncology Accelerates Phase 3 Data Readout to First Half of 2026
- Significant Stock Surge: Shares of CG Oncology Inc soared 21.8% to $51.05 after the announcement of an expedited topline data readout for the PIVOT-006 clinical trial, reflecting strong market confidence in the company's future prospects.
- Clinical Trial Advancement: The trial compares adjuvant intravesical treatment versus surveillance in patients with intermediate-risk non-muscle invasive bladder cancer, and the earlier data release is expected to attract more investor interest, further propelling the company's growth.
- Positive Market Reaction: This stock price increase not only indicates investor optimism about CG Oncology's potential but may also enhance the company's financing capabilities in the biopharmaceutical sector, strengthening its competitive position.
- Significant Industry Impact: CG Oncology's progress could influence treatment standards for non-muscle invasive bladder cancer, prompting other companies in the industry to accelerate their R&D efforts, thereby boosting overall market vitality.
See More
